Printer Friendly

/ C O R R E C T I O N - SPEAR FINANCIAL/

 In SF004, Spear Financial Results, moved earlier today, the table entry for fourth quarter 1992 weighted average shares outstanding primary and fully diluted should read "7,445,556," rather than "7,450,656" and the table entry for the year-to-date 1992 weighted average shares outstanding primary and fully diluted should read "7,531,936," rather than "7,631,936," as originally issued.
 -0- 3/31/93 C SF004
 /PRNewswire -- March 31/
 (SFNS)


CO: Spear Financial Services Inc.; James Mitchell & Co. ST: California IN: FIN SU: ERN

SG -- SF004A -- 1453 03/31/93 11:14 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:95
Previous Article:CHASE MORTGAGE FINANCE CORP. SERIES 1993E CLASS A 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:AMERICAN BUSINESS PRODUCTS RESUMES STOCK REPURCHASE
Topics:


Related Articles
CONVERGENT SOLUTIONS RELEASES CS/ADS 6.4 DATABASE INDEPENDENT 4GL WITH INTERFACE TO INFORMIX
IBM AND MULTI SOFT SIGN SOFTWARE MARKETING AGREEMENT
DCA ANNOUNCES SELECT COMM SERVER WITH PC ROUTER SUPPORT
IBM AND MULTI SOFT SIGN ADDITIONAL MARKETING AGREEMENT
IBM AND MULTI SOFT SIGN THIRD INTERNATIONAL MARKETING AGREEMENT; COVERING EUROPE, THE MIDDLE EAST AND AFRICA
CompuServe, Golden CommPass Team Up To Reach OS-2 Market
Symantec Supports OS/2 Customers With New Antivirus Product
Compuware Delivers Enhanced Enterprise Test Data Management Solution; Compuware File-AID/CS 3.0 Offers Rich Data-Management Functionality With...
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.
Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters